Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review

Cancer

Volumn 106, Issue 1, 2006, Pages 223-233

  Lyman, Gary H ^a,c   Glaspy, John ^b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Chemotherapy induced anemia; Early intervention; Erythropoietin; Relative risk

Indexed keywords

ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PATIENT; DAILY LIFE ACTIVITY; ERYTHROPOIESIS; HUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW;

ANEMIA; ANTINEOPLASTIC AGENTS; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN; HEMOGLOBINS; HUMANS; NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS;

EID: 29744450260     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21570     Document Type: Review

References (40)

1. Curt GA. Impact of fatigue on quality of life in oncology patients. Semin Hematol. 2000;37(Suppl 6):14-17.
2. Balducci L. Epidemiology of anemia in the elderly, information on diagnostic evaluation. J Am Geriatr Soc. 2003;51(3 Suppl):S2-9.
3. Cancer Therapy Evaluation Program (CTEP). Common toxicity criteria, v. 2.0. DCTD, NCI, HIH, DHHS. March 1998. Available from URL: http://www.fda.gov/ cder/cancer/toxicityframe. htm. [Accessed February 2004].
4. Food and Drug Administration/Center for Drug Evaluation and Research Oncology Tools page. World Health Organization toxicity criteria. Food and Drug Administration Web site. Available from URL: http://www.fda. gov/cder/cancer/toxicityframe.htm. [Accessed February 2004].
5. Groopman IE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999;91:1616-1634.
6. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood. 2002;100:2303-2320.
7. Seidenfeld J, Piper M, Flamm C, et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst. 2001;93:1204-1214.
8. Del Mastro L, Venturini M, Lionetto R, et al. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol. 1997;15:2715-2721.
9. ten Bokkel Huinink WW, de Swart CAM, van Toorn DW, et al. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol. 1998;15:174-182.
10. Thatcher N, De Campos ES, Bell DR, et al. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer. 1999;80:396-402.
11. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B, and the Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19:2865-2874.
12. Fairclough D, Gagnon D, Zagari M, Marschner N, Dicato M. Evaluation of quality of life in a clinical trial with nonrandom dropout: the effect of epoetin alfa in anemic cancer patients. Qual Life Res. 2003;12:1013-1027.
13. Fallowfield L, Gagnon D, Zagari M, et al. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. Br J Cancer. 2002;87:1341-1353.
14. Cella D, Kallich J, McDermott A, Xu X. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol. 2004;15:979-986.
15. Higgins JP, Thompson SG, Deeks IJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J. 2003;327:557-560.
16. Mantel N. Chi-square tests with one degree of freedom: extensions of the Mantel-Haenszel procedure. J Am Stat Assoc. 1964;58:163-170.
17. Fleiss J. The statistical basis of meta-analysis. Stat Methods Med Res. 1993;2:121-145.
18. Gart JJ, Zweiful JR. On the bias of various estimators of the logit and its variance with applications to quantal bioassay. Biometrika. 1967;54:181-187.
19. Haldane JBS. The estimation and significance of the logarithm of a ratio of frequencies. Ann Hum Genet. 1956;20:309-311.
20. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 2002;94:1211-1220.
21. Kunikane H, Watanabe K, Fukuoka M, et al. Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer. Int J Clin Oncol. 2001;6:296-301.
22. Crawford I, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002;95:888-895.
23. Littlewood TJ, Nortier J, Rapoport B, et al. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy. Hematol Oncol. 2003;21:169-180.
24. Bamias A, Aravantinos G, Kalofonos C, et al. Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human erythropoietin (rHuEPO): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group. Oncology. 2003;64:102-110.
25. Vansteenkiste J, Tomita D, Rossi G, Pirker R. Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline. Support Care Cancer. 2004;12:253-262.
26. Straus DJ, Riggs SA, Tulpule A, Sarokhan B. Early treatment with epoetin alfa improves anemia, quality of life (QOL), and productivity in patients (pts) with hematologic malignancies and mild anemia during chemotherapy (CT) [abstract 1811]. Blood. 2003;102.
27. Chang J, Couture F, for the Caradian Eprex Study Group. Once weekly epoetin alfa maintains hemoglobin, improves quality of life and reduces transfusion in breast cancer patients receiving chemotherapy [presentation]. 2003 ASCO Annual Meeting. Available from URL: http://media.asco.org/asco/ meetings_education/vm/2003/slides_only/2003/ 2309/PPT/01.gif. [Accessed March 2004].
28. Crawford J, Robert F, Perry M, Belani C, Sarokhan B. Epoetin alfa 40,000 U once weekly maintains hemoglobin in advanced non-small-cell lung cancer patients receiving first-line chemotherapy [presentation]. 2003 ASCO Annual Meeting. Available from URL: http://media.asco. org/asco/meetings_education/vm/ 2003/slides_only/ frame.asp?ID = 2055. [Accessed March 2004].
29. Rearden T, Charu V, Saidman B, et al. Results of a randomized study of every-three week dosing (Q3W) of darbepoetin alfa for chemotherapy-induced anemia (CIA) [presentation]. 2004 ASCO Annual Meeting. Available from URL: http:// www.asco.org/ac/1,1003,_12-002643-00_18-0026-00_19-002479,00.asp. [Accessed July 2004].
30. Savonije J, Van Groeningen C, Van Bochove A, Pinedo HG. Early intervention with epoetin-alfa during platinum-based chemotherapy [presentation]. 2004 ASCO Annual Meeting. Available from URL: http://www.asco.org/ac/ 1,1003,_12-002511-00_18-0026-00_19-009068,00.asp. [Accessed July 2004].
31. Littlewood T, Bajetta E. Early administration of epoetin alfa optimizes anemia management with respect to hematologic and quality of life outcomes in anemia cancer patients undergoing chemotherapy [abstract 3524]. Blood. 2002;100:18b.
32. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol. 1997;15:1218-1234.
33. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol. 1998;16:3412-3425.
34. Gralow JR, Hudis CA, Williams D. Incremental improvements in QOL related to changes in hemoglobin in breast cancer (BC) patients (pts) receiving adjuvant chemotherapy (ADJCT) and QW epoetin alfa therapy [abstract 4392]. Blood. 2003;102.
35. Rodgers GM, editor. Guidelines for supportive care: cancer and treatment-related anemia. v.2.2004 ed: National Comprehensive Cancer Network Available from URL: http://www.nccn.org/physician_gls/index.html [accessed March 24, 2005].
36. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960-5972.
37. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255-1260.
38. Kaanders JHAM, van der Kogel AJ. Erythropoetin to treat anaemia in patients with head and neck cancer [letter: comment]. Lancet. 2004;363:79-80.
39. Leyland-Jones B, Salaheddin M. Erythropoetin to treat anaemia in patients with head and neck cancer [letter: comment]. Lancet. 2004;363:80.
40. Haddad R, Posner M. Erythropoetin to treat anaemia in patients with head and neck cancer [letter: comment]. Lancet. 2004;363:79.